A Pilot Study to Evaluate the Use of the Vest® System for Treatment of Bronchiectasis Patients in the Home Setting
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04017312|
Recruitment Status : Recruiting
First Posted : July 12, 2019
Last Update Posted : February 17, 2020
|Condition or disease||Intervention/treatment||Phase|
|Bronchiectasis Bronchiectasis With Acute Exacerbation||Device: High Frequency Chest Wall Oscillation Device: Oscillating Positive Expiratory Pressure (OPEP)||Not Applicable|
Patients with NCFBE who require regular home airway clearance therapy will be eligible to be screened for inclusion in the study.
After enrollment, baseline data including demographics, pulmonary related medical history including acute exacerbations (pulmonary-related hospitalizations, ED visits and physician office visits) will be collected Pulmonary function tests (PFTs) (spirometry), and a six-minute walk test will be completed. Quality of Life measures and inflammatory markers and will be collected.
Patients will be randomized to HFCWO or OPEP therapy. Each device will be used within the approved product labeling. These will be the primary airway clearance devices for these patients during the 12 months of the study period.
Following enrollment in the study and completion of a baseline visit, subjects will be seen for follow-up visits.
Detailed documentation of health status and medical history will be collected during the 12-month study period and/or at each study visit to document the occurrence of acute exacerbations and to determine time to first exacerbation, number of hospitalizations and hospitalization days, number of ICU admissions and ICU days, and number of outpatient visits (Physician's office visit, Urgent Care Visits, ED visits)
At 3 months, 6 months and 12 months following the baseline visit, the following tests/procedures will be performed. At each follow-up study visit:
- Acute exacerbations that occurred during the prior 3-month period will be documented/verified
- Pulmonary function will be assessed using standard spirometry to obtain FEV1, FVC and FEV1/FVC.
- 6-minute walk test will be completed to assess respiratory status and endurance
- The QoL-B quality of life survey will be conducted
- A sputum sample will be collected. Sputum samples will be transported to a central lab to test for inflammatory markers (sputum neutrophil elastase in μg/ml).
Mean adherence to the prescribed treatment regimen will be collected and assessed using the validated Modified Self-Reported Medication-Taking Scale. Adherence data in the HFCWO arm will also be collected via the VisiView patient portal.
Adherence results will be collected at the 3-month visit, 6-month visit and 12-month visits.
Any device related adverse events which occur after initial therapy with The Vest® System or Acapella therapy will be recorded.
Any equipment related complaints which occur after initial therapy with The Vest® System or Acapella therapy will be recorded.
At the end of the 12-month study period, subjects randomized to the PEP group will be given the option of receiving HFCWO therapy for a 6 month follow up period with outcomes data assessed at the 6-month time point.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||70 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||The study will be a non-blinded prospective Randomized Control Trial (RCT) pilot study with subjects requiring airway clearance therapy randomized to Oscillating Positive Expiratory Pressure (OPEP) therapy as the control group and High Frequency Chest Wall Oscillation (HFCWO) therapy as the intervention group|
|Masking:||None (Open Label)|
|Official Title:||Evaluation of HFCWO Using The Vest® System for Treatment of Non-Cystic Fibrosis Bronchiectasis in the Home Setting|
|Actual Study Start Date :||August 23, 2019|
|Estimated Primary Completion Date :||November 2020|
|Estimated Study Completion Date :||November 2020|
Active Comparator: HFCWO group
Subjects in this arm of treatment will use The Vest® as their primary airway clearance modality for the duration of the study.
Device: High Frequency Chest Wall Oscillation
High frequency chest wall oscillation (HFCWO) therapy (also known as high-frequency chest-wall compression or HFCWC) is commonly prescribed to provide routine airway clearance in patients with bronchiectasis as well as other patients with a need for regular airway clearance therapy. HFCWO generates high velocity expiratory airflow. This airflow is thought to mobilize secretions by the sheer force created, effecting changes in rheology and moving mucus in a cephalad direction during the oscillation. The Vest® Airway Clearance System, a commonly used device, generates HFCWO using an air pulse generator and an inflatable garment that delivers pressure pulses to the thorax. These pressure pulses within the garment create HFCWO.
Other Name: The Vest® Airway Clearance System
Active Comparator: OPEP group
Subjects in this arm of treatment will use the Acapella® as their primary airway clearance modality for the duration of the study.
Device: Oscillating Positive Expiratory Pressure (OPEP)
Oscillating PEP is an airway clearance technique, where the person blows all the way out many times through a device. These types of oscillating PEP devices work in two ways. Firstly, they use resistance to make it more difficult during the breath out, like non-oscillating PEP devices. Oscillating PEP devices also create vibrations when breathing out. The vibrations move mucus from the surface of the airways. After blowing through the device several times, the person will huff and cough to clear the mucus from the lungs.
Other Name: Acapella®
- Frequency of acute exacerbations of bronchiectasis [ Time Frame: 12 months ]
Acute exacerbation periods will be defined as per the European Respiratory Society consensus definition:
A deterioration in three or more of the following key symptoms for at least 48 h:
- Sputum volume and/or consistency
- Sputum purulence
- Breathlessness and/or exercise tolerance
- Fatigue and/or malaise;
- Hemoptysis AND
- A clinician determines that a change in bronchiectasis treatment is required
- 6-minute walk test [ Time Frame: 12 months ]The 6-min walk test (6 MWT) is a submaximal exercise test that entails measurement of distance walked over a span of 6 minutes. The 6-minute walk distance (6 MWD) provides a measure for integrated global response of multiple cardiopulmonary and musculoskeletal systems involved in exercise. It will provide information regarding functional capacity and response to therapy.
- Pulmonary function tests [ Time Frame: 12 months ]FVC, FEV1 and FEV1/FVC as indicators of pulmonary function will be assessed using standard spirometry
- Quality of life measure using the Quality of Life - Bronchiectasis (QoL-B) tool [ Time Frame: 12 months ]The Quality of Life-Bronchiectasis (QoL-B), a self-administered, patient-reported outcome measure assessing symptoms, functioning and health-related quality of life for patients with NCFBE, contains 37 items on 8 scales (Respiratory Symptoms, Physical, Role, Emotional and Social Functioning, Vitality, Health Perceptions and Treatment Burden)
- Time to first exacerbation [ Time Frame: 12 months ]The duration of time from initiation of therapy to occurrence of an episode of acute exacerbation of bronchiectasis
- Number of exacerbation related hospitalizations [ Time Frame: 12 months ]This is the total number of times the subject was admitted as an inpatient due to symptoms of an acute exacerbation
- Number of exacerbation related inpatient hospital days [ Time Frame: 12 months ]This is the total number of days the subject spent in an inpatient non-ICU setting due to symptoms of an acute exacerbation
- Number of exacerbation related ICU admissions [ Time Frame: 12 months ]This is the total number of times the subject got admitted into an ICU facility due to symptoms of an acute exacerbation
- Number of exacerbation related ICU days [ Time Frame: 12 months ]This is the total number of days the subject spent in an ICU due to symptoms of an acute exacerbation
- Number of exacerbation related outpatient visits (Physician's office, Urgent Care Visits, ED visits) [ Time Frame: 12 months ]This is the total number of times the subject visited an outpatient healthcare facility due to symptoms of an acute exacerbation
- Number of courses of antibiotics during episodes of acute exacerbation [ Time Frame: 12 months ]This is the total courses of antibiotics prescribed for acute exacerbations
- Number of antibiotic use days during episodes of acute exacerbation [ Time Frame: 12 months ]This is the total number of days spent on antibiotics for acute exacerbations
- Inflammation - measured by sputum neutrophil elastase level [ Time Frame: 12 months ]Sputum will be collected at every visit and transported to a central lab for a sputum neutrophil elastase test in μg/ml
- Mean adherence to prescribed treatment regimen [ Time Frame: 12 months ]Adherence data will be collected using the Modified Self-Reported Medication Taking Scale and verified via the VisiView patient portal
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04017312
|Contact: Missy Wanjala, MD, MMCiemail@example.com|
|Contact: Brian Becker, RRT, M.Ed.||firstname.lastname@example.org|
|United States, New York|
|NYU Langone Health||Recruiting|
|New York, New York, United States, 10016|
|Contact: Stephanie Lau, MD 212-263-7951 email@example.com|
|United States, Tennessee|
|Tennessee Comprehensive Lung and Sleep Center||Recruiting|
|Nashville, Tennessee, United States, 37075|
|Contact: Wanda Smith, RN 615-431-0469 firstname.lastname@example.org|
|Principal Investigator:||Mark Jennings, MD||Johns Hopkins University|